Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The role of the adaptive immune response in controlling the growth and recurrence of human tumors has been controversial. We characterized the tumor-infiltrating immune cells in large cohorts of human colorectal cancers by gene expression profiling and in situ immunohistochemical staining. Collectively, the immunological data (the type, density, and location of immune cells within the tumor samples) were found to be a better predictor of patient survival than the histopathological methods currently used to stage colorectal cancer. The results were validated in two additional patient populations. These data support the hypothesis that the adaptive immune response influences the behavior of human tumors. In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In CRC, Tregs situated in the tumor mesenchyme result in a better prognosis, whereas Tregs residing in the tumor nests and infiltrating margins are linked to unfavorable clinical outcomes [142, 143].”
From Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review (2024) · cites this paper as [142]
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Research works printed but not linked: 3
- D. Pardoll, Nature411, 1010 (2001).
- Y. Naito et al., Cancer Res.58, 3491 (1998).
- We thank A. Rodi and M. Pelegrin for expert technical assistance; I. Gresser for helpful comments and critical review of the manuscript; and D. Frucht C. Anderson and T. Pokrovska for critically reading the manuscript. Supported by the Association pour la Recherche sur le Cancer (ARC) through the Alliance pour la Recherche sur le Cancer network (ARECA) INSERM Action Concertée Incitative ACI IMPBio Université Paris-Descartes Paris 5 and the Austrian Federal Ministry of Education Science and Culture (GBN-AU project Bioinformatics Integration Network).
Cited by
Items 801–900 of 1,043
Liu, S., Guo, W., Shi, J., Li, N., Yu, X., Xue, J., Fu, X., Chu, K., Lu, C., Zhao, J., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.008 · Cited by 159
Sun, J., Chen, L.-J., Zhang, G.-B., Jiang, J.-T., Zhu, M., Tan, Y., Wang, H.-T., Lu, B.-F., & Zhang, X.-G. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0841-1 · Cited by 159
Role of LFA-1 and ICAM-1 in Cancer
Reina, M., & Espel, E. (2017) · Cancers · doi:10.3390/cancers9110153 · Cited by 159
Predictive biomarkers of colon cancer immunotherapy: Present and future
Hou, W., Cheng, Y., & Zhu, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032314 · Cited by 159
Rejection versus escape: the tumor MHC dilemma
Garrido, F., Ruiz-Cabello, F., & Aptsiauri, N. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1947-x · Cited by 158
Detailed analysis of inflammatory cell infiltration in colorectal cancer
Väyrynen, J. P., Tuomisto, A., Klintrup, K., Mäkelä, J., Karttunen, T. J., & Mäkinen, M. J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.508 · Cited by 158
Sui, S., An, X., Xu, C., Li, Z., Hua, Y., Huang, G., Sui, S., Long, Q., Sui, Y., Xiong, Y., et al. (2020) · Theranostics · doi:10.7150/thno.49451 · Cited by 158
Role of prostanoids in gastrointestinal cancer
Wang, D., & DuBois, R. N. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97953 · Cited by 158
Toor, S. M., Murshed, K., Al-Dhaheri, M., Khawar, M., Abu Nada, M., & Elkord, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02936 · Cited by 158
Enhancing Tumor T Cell Infiltration to Enable Cancer Immunotherapy
Zhang, J., Endres, S., & Kobold, S. (2019) · Immunotherapy · doi:10.2217/imt-2018-0111 · Cited by 158
Tracking Cancer Evolution through the Disease Course
Bailey, C., Black, J. R. M., Reading, J. L., Litchfield, K., Turajlic, S., McGranahan, N., Jamal-Hanjani, M., & Swanton, C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1559 · Cited by 158
Chen, W., Lai, Y., Chen, H., Guo, H., Su, I., & Chen, H. H. W. (2013) · Histopathology · doi:10.1111/his.12156 · Cited by 139
CD8+ and FOXP3+ Tumor-Infiltrating T Cells Before and After Chemoradiotherapy for Rectal Cancer
Shinto, E., Hase, K., Hashiguchi, Y., Sekizawa, A., Ueno, H., Shikina, A., Kajiwara, Y., Kobayashi, H., Ishiguro, M., & Yamamoto, J. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3584-y · Cited by 158
Boland, C. R., & Lynch, H. T. (2013) · Familial Cancer · doi:10.1007/s10689-013-9637-8 · Cited by 158
Nászai, M., Kurjan, A., & Maughan, T. (2021) · Cancer Medicine · doi:10.1002/cam4.4143 · Cited by 158
Yamazaki, T., Gunderson, A. J., Gilchrist, M., Whiteford, M., Kiely, M. X., Hayman, A., O'Brien, D., Ahmad, R., Manchio, J. V., Fox, N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00446-6 · Cited by 147
Huang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0407 · Cited by 157
“An intratumoral infiltrate with activated T cells has prognostic significance in patients with cancer, where primary tumors with larger and more diffuse T cell infiltrates displaying an effector functional phenotype have improved survival (26, 27).”
Chmielewski, M. M., & Abken, H. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1202-z · Cited by 157
Harvey, R. D., & Morgan, E. T. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.143 · Cited by 156
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression.
Koelwyn, G. J., Wennerberg, E., Demaria, S., & Jones, L. W. (2015) · PubMed · Cited by 157
Zhang, J., Ji, Z., Caushi, J. X., El Asmar, M., Anagnostou, V., Cottrell, T. R., Chan, H. Y., Suri, P., Guo, H., Merghoub, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2931 · Cited by 152
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
Sauer, N. J., Janicka, N., Szlasa, W., Skinderowicz, B., Kołodzińska, K., Dwernicka, W., Oślizło, M., Kulbacka, J., Novickij, V., & Karłowicz-Bodalska, K. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03516-1 · Cited by 157
Cancer Immunotherapy: Accomplishments to Date and Future Promise
Helmy, K. Y., Patel, S. A., Nahas, G. R., & Rameshwar, P. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.88 · Cited by 156
Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
Galon, J., Fox, B. A., Bifulco, C. B., Masucci, G., Rau, T., Botti, G., Marincola, F. M., Ciliberto, G., Pages, F., Ascierto, P. A., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1029-z · Cited by 141
Self-citationTu, J.-F., Ding, Y.-H., Ying, X.-H., Wu, F.-Z., Zhou, X.-M., Zhang, D.-K., Zou, H., & Ji, J.-S. (2016) · Scientific Reports · doi:10.1038/srep35056 · Cited by 144
Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies
Petitprez, F., Vano, Y. A., Becht, É., Giraldo, N. A., de Reyniès, A., Sautès‐Fridman, C., & Fridman, W. H. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2058-z · Cited by 156
Self-citationImaging activated T cells predicts response to cancer vaccines
Alam, I. S., Mayer, A. T., Sagiv-Barfi, I., Wang, K., Vermesh, O., Czerwinski, D. K., Johnson, E. M., James, M. L., Levy, R., & Gambhir, S. S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98509 · Cited by 156
Carrero, R. M. S., Beceren‐Braun, F., Rivas, S., Hegde, S., Gangadharan, A., Plote, D., Pham, G., Anthony, S. M., & Schluns, K. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814642116 · Cited by 156
Pateras, I. S., Havaki, S., Nikitopoulou, X., Vougas, K. N., Townsend, P. A., Panayiotidis, M. I., Georgakilas, A. G., & Gorgoulis, V. G. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.011 · Cited by 156
Immune evasion of microsatellite unstable colorectal cancers
Kloor, M., Michel, S., & von Knebel Doeberitz, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25283 · Cited by 138
Interleukins 1 and 6 as main mediators of inflammation and cancer
Dmitrieva, O., Shilovskiy, I. P., Khaitov, M. R., & Grivennikov, S. I. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916020024 · Cited by 156
Hladíková, K., Koucký, V., Bouček, J., Laco, J., Grega, M., Hodek, M., Zábrodský, M., Vošmik, M., Rozkošová, K., Vošmiková, H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0726-6 · Cited by 155
Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma
Leuchte, K., Staib, E., Thelen, M., Gödel, P., Lechner, A., Zentis, P., Garcia-Marquez, M. A., Waldschmidt, D., Datta, R. R., Wahba, R., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02734-1 · Cited by 155
Advancements in combining targeted therapy and immunotherapy for colorectal cancer
Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S., & Kopetz, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.05.001 · Cited by 155
Deng, L., Zhang, H., Luan, Y., Zhang, J., Xing, Q. R., Dong, S., Wu, X., Liu, M., & Wang, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1073 · Cited by 155
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective
Desjarlais, J. R., Lazar, G. A., Zhukovsky, E. A., & Chu, S. Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.009 · Cited by 154
Britten, C. M., Gouttefangeas, C., Welters, M. J. P., Pawelec, G., Koch, S., Ottensmeier, C., Mander, A., Walter, S., Paschen, A., Müller-Berghaus, J., et al. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0378-0 · Cited by 144
Experimental mouse tumour models: what can be learnt about human cancer immunology?
Dranoff, G. (2011) · Nature reviews. Immunology · doi:10.1038/nri3129 · Cited by 154
Lopci, E., Toschi, L., Grizzi, F., Rahal, D., Olivari, L., Castino, G. F., Marchetti, S., Cortese, N., Qehajaj, D., Pistillo, D., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3425-2 · Cited by 154
A Believer’s Overview of Cancer Immunosurveillance and Immunotherapy
Finn, O. J. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701302 · Cited by 138
Nath, S., Obaid, G., & Hasan, T. G. (2019) · Photochemistry and Photobiology · doi:10.1111/php.13173 · Cited by 154
Infiltrating lymphocytes and human papillomavirus‐16–associated oropharyngeal cancer
Wansom, D., Light, E., Thomas, D., Worden, F. P., Prince, M. E., Urba, S. G., Chepeha, D. B., Kumar, B., Cordell, K. G., Eisbruch, A., et al. (2011) · The Laryngoscope · doi:10.1002/lary.22133 · Cited by 153
Fritzsching, B., Fellenberg, J., Moskovszky, L., Sápi, Z., Krenacs, T., Machado, I., Poeschl, J., Lehner, B., Szendrõi, M., Bosch, A. L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.990800 · Cited by 140
Cézé, N., Thibault, G., Goujon, G., Viguier, J., Watier, H., Dorval, E. D., & Lecomte, T. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1610-3 · Cited by 153
Katz, S. C., Pillarisetty, V. G., Bamboat, Z. M., Shia, J., Hedvat, C. V., Gönen, M., Jarnagin, W. R., Fong, Y., Blumgart, L. H., D'Angelica, M. I., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0585-3 · Cited by 153
Regulation of NK Cell Function by Human Granulocyte Arginase
Oberlies, J., Watzl, C., Giese, T., Luckner, C., Kropf, P., Müller, I., Ho, A. D., & Munder, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803523 · Cited by 139
Carruthers, R., Tho, L. M., Brown, J., Kakumanu, S., McCartney, E., & McDonald, A. C. (2012) · Colorectal Disease · doi:10.1111/j.1463-1318.2012.03147.x · Cited by 153
Harnessing the immune system to treat cancer
Bhardwaj, N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32136 · Cited by 152
Freund, E., Liedtke, K. R., van der Linde, J., Metelmann, H., Heidecke, C.-D., Partecke, L.-I., & Bekeschus, S. (2019) · Scientific Reports · doi:10.1038/s41598-018-37169-3 · Cited by 152
Gupta, R. G., Li, F., Roszik, J., & Lizee, G. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1575 · Cited by 152
Ye, B., Fan, J., Xue, L., Yu, Z., Luo, P., Jiang, A., Xie, J., Li, Q., Liang, X., Tan, J., et al. (2025) · iMeta · doi:10.1002/imt2.70011 · Cited by 152
Yasuda, K., Nirei, T., Sunami, E., Nagawa, H., & Kitayama, J. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-49 · Cited by 152
Transforming Growth Factor β: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer?
Yang, L., & Moses, H. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2556 · Cited by 151
“lular carcinoma (34) and colorectal tumors predicting clinical outcome (35).”
The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis
Itatani, Y., Kawada, K., Inamoto, S., Yamamoto, T., Ogawa, R., Taketo, M., & Sakai, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050643 · Cited by 132
Yao, W., He, J., Yang, Y., Wang, J., Qian, Y., Yang, T., & Ji, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-08128-1 · Cited by 152
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine
Nebot-Bral, L., Brandão, D., Verlingue, L., Rouleau, É., Caron, O., Despras, E., Dakdouki, Y. E., Champiat, S., Aoufouchi, S., Leary, A. F., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.026 · Cited by 151
Kordbacheh, T., Honeychurch, J., Blackhall, F. H., Finn, C. F., & Illidge, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx790 · Cited by 151
Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer
Goehrig, D., Nigri, J., Samain, R., Wu, Z., Cappello, P., Gabiane, G., Zhang, X., Zhao, Y., Kim, I.-S., Chanal, M., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317570 · Cited by 131
Bergamaschi, C., Pandit, H., Nagy, B. A., Stellas, D., Jensen, S. M., Bear, J., Cam, M., Valentin, A., Fox, B. A., Felber, B. K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000599 · Cited by 141
Artificial intelligence to identify genetic alterations in conventional histopathology
Cifci, D., Foersch, S., & Kather, J. N. (2022) · The Journal of Pathology · doi:10.1002/path.5898 · Cited by 126
Morse, M. A., Niedzwiecki, D., Marshall, J. L., Garrett, C. H., Chang, D. Z., Aklilu, M., Crocenzi, T. S., Cole, D. J., Dessureault, S., Hobeika, A. C., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318292919e · Cited by 150
The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform
Schachtschneider, K. M., Schwind, R. M., Newson, J. L., Kinachtchouk, N., Rizko, M., Mendoza-Elias, N., Grippo, P. J., Principe, D. R., Park, A. J., Overgaard, N. H., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00190 · Cited by 150
Fusobacterium and Colorectal Cancer
Zhou, Z., Chen, J., Yao, H., & Hu, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00371 · Cited by 150
Kuwahara, T., Hazama, S., Suzuki, N., Yoshida, S., Tomochika, S., Nakagami, Y., Matsui, H., Shindo, Y., Kanekiyo, S., Tokumitsu, Y., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0559-6 · Cited by 150
Si, Y., Merz, S. F., Jansen, P., Wang, B.-X., Bruderek, K., Altenhoff, P., Mattheis, S., Lang, S., Gunzer, M., Klode, J., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw9159 · Cited by 150
Spontaneous and Induced Animal Models for Cancer Research
Onaciu, A., Munteanu, R. A., Munteanu, V. C., Gulei, D., Ráduly, L., Feder, R., Pîrlog, R., Atanasov, A. G., Korban, S. S., Irimie, A., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10090660 · Cited by 150
Ballhausen, A., Przybilla, M. J., Jendrusch, M., Haupt, S., Pfaffendorf, E., Seidler, F., Witt, J., Hernandez Sanchez, A., Urban, K., Draxlbauer, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18514-5 · Cited by 139
Neoadjuvant immunotherapy in primary and metastatic colorectal cancer
Kanani, A. N., Veen, T., & Søreide, K. (2021) · British journal of surgery · doi:10.1093/bjs/znab342 · Cited by 150
Wang, T.-B., Guo, K., Zhang, D., Wang, H., Yin, J., Cui, H., & Wu, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110368 · Cited by 152
Defensins: “Simple” antimicrobial peptides or broad-spectrum molecules?
Suarez‐Carmona, M., Hubert, P., Delvenne, P., & Herfs, M. F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.12.005 · Cited by 149
Molecular subtypes in cancers of the gastrointestinal tract
Bijlsma, M. F., Sadanandam, A., Tan, P. B. O., & Vermeulen, L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.33 · Cited by 150
Pradeu, T. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108616706 · Cited by 149
Yi, M., Li, A., Zhou, L., Chu, Q., Luo, S., & Wu, K. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02817-z · Cited by 149
Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 149
Deep learning in cancer genomics and histopathology
Unger, M., & Kather, J. N. (2024) · Genome Medicine · doi:10.1186/s13073-024-01315-6 · Cited by 152
The Prognostic Value of Tumor-Infiltrating Neutrophils in Gastric Adenocarcinoma after Resection
Zhao, J.-J., Pan, K., Wang, W., Chen, J.-G., Wu, Y.-H., Lv, L., Li, J.-J., Chen, Y.-B., Wang, D.-D., Pan, Q.-Z., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033655 · Cited by 135
Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway
Chahal, H., Trivellin, G., Leontiou, C. A., Alband, N., Fowkes, R. C., Tahir, A., Igreja, S., Chapple, J. P., Jordan, S., Lupp, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1111 · Cited by 150
Swords into plowshares: IL-23 repurposes tumor immune surveillance
Langowski, J. L., Kastelein, R. A., & Oft, M. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.03.006 · Cited by 149
Muthuswamy, R., Berk, E., Junecko, B. F., Zeh, H. J., Zureikat, A. H., Normolle, D., Luong, T. M., Reinhart, T. A., Bartlett, D. L., & Kalinski, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4136 · Cited by 138
Stress, Immunity, and Cervical Cancer: Biobehavioral Outcomes of a Randomized Clinical Trail
Nelson, E. L., Wenzel, L. B., Osann, K., Dogan-Ates, A., Chantana, N., Reina-Patton, A., Laust, A. K., Nishimoto, K. P., Chicz-DeMet, A., du Pont, N., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1632 · Cited by 137
Cano‐Mejia, J., Burga, R. A., Sweeney, E. E., Fisher, J. P., Bollard, C. M., Sandler, A. D., Cruz, C. C., & Fernandes, R. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.10.015 · Cited by 148
Current status of immunotherapy in metastatic colorectal cancer
Wróbel, P., & Ahmed, S. (2018) · International Journal of Colorectal Disease · doi:10.1007/s00384-018-3202-8 · Cited by 148
Zhong, Q., Fang, Y., Lai, Q., Wang, S., He, C., Li, A., Liu, S., & Yan, Q. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01637-4 · Cited by 148
The Tumor Microenvironment: A Pitch for Multiple Players
Schiavoni, G., Gabriele, L., & Mattei, F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00090 · Cited by 147
Characterization of tumor-associated B-cell subsets in patients with colorectal cancer
Shimabukuro-Vornhagen, A., Schlößer, H. A., Gryschok, L., Malcher, J., Wennhold, K., Garcia-Marquez, M., Herbold, T., Neuhaus, L. S., Becker, H. J., Fiedler, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1701 · Cited by 127
Mohammed, Z. M. A., Going, J. J., Edwards, J., Elsberger, B., & McMillan, D. C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.493 · Cited by 148
Nawaz, S., Heindl, A., Koelble, K., & Yuan, Y. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.37 · Cited by 147
Immune regulation of metastasis: mechanistic insights and therapeutic opportunities
Blomberg, O. S., Spagnuolo, L., & de Visser, K. E. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.036236 · Cited by 148
Yaqub, S., Henjum, K., Mahic, M., Jahnsen, F. L., Aandahl, E. M., Bjørnbeth, B. A., & Taskén, K. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0417-x · Cited by 147
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Strome, S. E., Sausville, E. A., & Mann, D. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1084 · Cited by 147
Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics
Zanetti, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402669 · Cited by 118
Liu, H., Zhang, T., Jin, Y., Li, H., Huang, J., Li, X., Wu, B., Huang, X., & Hou, J. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1231-7 · Cited by 146
Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis
Reissfelder, C., Stamova, S., Gossmann, C., Braun, M., Bonertz, A., Walliczek, U., Grimm, M., Rahbari, N. N., Koch, M., Saadati, M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci74894 · Cited by 142
Chia, J., Yeo, K. P., Whisstock, J. C., Dunstone, M. A., Trapani, J. A., & Voskoboinik, I. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903815106 · Cited by 146
Kim, S. T., Jeong, H., Woo, O. H., Seo, J. H., Kim, A., Lee, E. S., Shin, S. W., Kim, Y. H., Kim, J. S., & Park, K. H. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182467d90 · Cited by 146
Brenner, E., Schörg, B. F., Ahmetlić, F., Wieder, T., Hilke, F. J., Simon, N., Schroeder, C., Demidov, G. M., Riedel, T., Fehrenbacher, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14987-6 · Cited by 147
Recent advances in drug delivery systems for enhancing drug penetration into tumors
He, B., Sui, X., Yu, B., Wang, S., Shen, Y., & Cong, H. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1831106 · Cited by 134
Yang, I., Han, S. J., Sughrue, M. E., Tihan, T., & Parsa, A. T. (2011) · Journal of Neurosurgery · doi:10.3171/2011.4.jns101172 · Cited by 127
IL-4-mediated drug resistance in colon cancer stem cells
Todaro, M., Alea, M. P., Scopelliti, A., Medema, J. P., & Stassi, G. (2008) · Cell Cycle · doi:10.4161/cc.7.3.5389 · Cited by 146
Ong, S., Tan, Y., Beretta, O., Jiang, D., Yeap, W., Tai, J. J. Y., Wong, W., Yang, H., Schwarz, H., Lim, K., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201141825 · Cited by 145
Metadata
- Authors
- Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoué, F., Bruneval, P., Cugnenc, P.-H., Trajanoski, Z., Fridman, W.-H., & Pagès, F.
- Affiliations
- INSERM U 255, Paris, 75006 France; Université Paris-Descartes Paris 5, Faculté de Médecine, Paris, 75006 France; and Université Pierre et Marie Curie Paris 6, Institut des Cordeliers, Paris, 75006 France.
- Inserm (FR)
- ORCID
- Venue
- Science
- Published
- 2006-09-29
- Volume
- 313
- Issue
- 5795
- Pages
- 1960-1964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2142300779
- Cited by
- 6,516
- References
- 31
- Citations by year
- 2026: 237 · 2025: 278 · 2024: 329 · 2023: 444 · 2022: 451 · 2021: 574 · 2020: 524 · 2019: 433 · 2018: 447 · 2017: 405 · 2016: 394 · 2015: 380 · 2014: 268 · 2013: 282 · 2012: 237
- FWCI
- 70.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- colorectal cancer, tumor-infiltrating immune cells, adaptive immune response, prognostic factors, patient survival, tumor immune microenvironment, gene expression profiling, cancer immunotherapy
- MeSH terms
- Female, Humans, Immunohistochemistry, Immunologic Memory, Lymphatic Metastasis, Male, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Colorectal Neoplasms, Cohort Studies, Survival Analysis, Polymerase Chain Reaction, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, CD3 Complex, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Th1 Cells, Disease Progression, Disease-Free Survival, Lymphocyte Count, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.